Jane Street Group, LLC Replimune Group, Inc. Transaction History

Jane Street Group, LLC

$481 Billion
Q2 2025

A detailed history of Jane Street Group, LLC transactions in Replimune Group, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 87,145 shares of REPL stock, worth $457,511. This represents 0.0% of its overall portfolio holdings.

Number of Shares

87,145

Previous 264,895 67.1%

Holding current value

$457,511

Previous $2.58 Million 68.67%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$6.92 - $10.38 $1.23 Million - $1.85 Million	-177,750 Reduced 67.1%	87,145 $809,000
Q1 2025 May 19, 2025	SELL	$9.75 - $14.31 $1.32 Million - $1.94 Million	-135,400 Reduced 33.83%	264,895 $2.58 Million
Q1 2025 May 14, 2025	BUY	$9.75 - $14.31 $819,078 - $1.2 Million	84,008 Added 26.56%	400,295 $3.9 Million
Q4 2024 Feb 14, 2025	BUY	$10.54 - $14.93 $569,571 - $806,802	54,039 Added 20.61%	316,287 $3.83 Million
Q3 2024 Nov 14, 2024	SELL	$8.09 - $11.23 $2.22 Million - $3.08 Million	-274,078 Reduced 51.1%	262,248 $2.87 Million
Q2 2024 Aug 14, 2024	BUY	$5.01 - $9.46 $1.9 Million - $3.58 Million	378,508 Added 239.84%	536,326 $4.83 Million
Q1 2024 May 15, 2024	SELL	$6.87 - $9.31 $588,717 - $797,811	-85,694 Reduced 35.19%	157,818 $1.29 Million
Q4 2023 Feb 14, 2024	BUY	$6.75 - $16.18 $1.64 Million - $3.94 Million	243,512 New	243,512 $2.05 Million
Q2 2023 Aug 14, 2023	BUY	$15.65 - $24.1 $1.01 Million - $1.55 Million	64,403 Added 398.51%	80,564 $1.87 Million
Q1 2023 May 15, 2023	SELL	$17.48 - $29.09 $541,355 - $900,917	-30,970 Reduced 65.71%	16,161 $285,000
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $805,468 - $1.32 Million	47,131 New	47,131 $1.28 Million

Others Institutions Holding REPL

# of Institutions

195

Shares Held

77.7M

Call Options Held

2.06M

Put Options Held

2.86M

View Full List

About Replimune Group, Inc.

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $259M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

More about REPL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account

Jane Street Group, LLC Replimune Group, Inc. Transaction History